Introduction {#S0001}
============

Community-acquired pneumonia (CAP) is an infectious disease with a clinical severity ranging from mild to life-threatening. CAP has high mortality rates and is costly to treat.[@CIT0001] In the US in 2012, the total direct medical costs related to CAP were estimated at US\$ 7,220 to US\$ 11,443.[@CIT0002] In European countries, the cost was estimated to be between €1,201 and €1,586 per patient. These high costs have been partially attributed to multiple antibiotic resistance.[@CIT0003]

Established international guidelines of the British Thoracic Society (BTS), American Thoracic Society (ATS), and National Institute for Health and Care Excellence (NICE) concur that empirical treatment of CAP with antibiotics is urgent considering the elevated mortality rates, the culture timing, and unspecified results from clinical and radiology methods for determining bacterial infections.[@CIT0004]--[@CIT0006] Additionally, abstaining from microbiological evaluation in clinical practices for empirical treatment of CAP patients potentially leads to antibiotic resistance and overuse, which indirectly contributes to hospitalization costs.[@CIT0007]--[@CIT0009] At present, the implementation of rapid, advanced molecular microbiology methods for CAP diagnostics has largely been developed.[@CIT0010] The extended use of these promising novel approaches, however, remains unavailable and costly in low-middle income countries (LMICs), which carry higher burdens of the disease. Controversies surrounding the recommendation for the use of microbiology tests in mild-moderate hospitalized cases and outpatient CAP management have been described by previous research since clinical improvement could be achieved by empirical antibiotics alone.[@CIT0011],[@CIT0012] The evaluation of sputum cultures from respiratory samples is recommended for inpatient CAP treatment, aiming to select appropriate antibiotics and prevent further antibiotic resistance.[@CIT0004],[@CIT0006],[@CIT0013]

When immediately employed, early directed therapy after evaluating culture results is an essential strategy to prevent high rates of antibiotic resistance. The implementation of culture analysis in developing countries with a high prevalence of CAP, such as Indonesia, should be considered alongside the assessment of culture analysis impact on costs and patient life expectancy (LE). Since 2014, Indonesia has employed a new universal health coverage program, which the health ministry contracted to a single public insurance company (Badan Penyelenggara Jaminan Sosial or BPJS). The universal health coverage also involves the implementation of a national social security system in managing expenditure related to reimbursement and costing in the national healthcare system, inclusive of cost-effectiveness considerations. Hitherto, the lack of evidence for cost-effectiveness has hampered the implementation of culture analysis as a diagnostic tool guiding the management of CAP. Therefore, the culture analysis approach has rarely been adopted in hospitals or in communities. Considering the current limitations of the evidence regarding the value of culture analysis prior to empirical-based antibiotic administration in CAP patients, we performed a cost-effectiveness analyses on the implementation of culture-based treatment (CBT) compared to empirical treatment only (ET) in hospitalized CAP patients.

Materials And Methods {#S0002}
=====================

Decision-Tree Model Overview {#S0002-S2001}
----------------------------

A decision-tree model was designed from individual patient data of hospitalized CAP patients in Indonesia. The model is shown in [Figure 1](#F0001){ref-type="fig"}. We built the model based on a payer perspective. The decision-tree compared two options: i) patients with empirical antibiotic treatment (ET) during hospitalization and ii) patients with CBT for whom medications were adjusted based on microbiological evaluation in terms of the culture and antimicrobial susceptibility tests. The culture analysis was conducted on samples from respiratory tracts (sputum) and blood draws. One package was produced for positive cultures demonstrating antimicrobial susceptibility after identification of the microorganisms. We assumed that the level of competencies and advances of the laboratory staff were equal in handling the specimens and reporting the results. The CBT group were treated with empirical antibiotics based on the Indonesian guidelines at 24 hrs post-admission. Thereafter, culture results were provided, and the patients were treated with the directed therapy involving a second round of antibiotics.[@CIT0014] The second round of antibiotics could be different from the previous empirical treatment (antibiotic change or AC) or be the same as (no antibiotic change or NC). We included in the AC group patients with negative cultures with no microorganism growth, for whom the physicians subsequently stopped the use of antibiotics. In the ET group, we assumed that the treatment using antibiotics was empirical during hospitalization. The termination states of the decision-tree for both CBT and ET were presented as recovery or death. Patients with no sputum available for culture tests were assumed to undergo empirical therapy during hospitalization, and we included such patients in the ET group. As there was no specific indication to the physician examining the culture of patients' sputum, we assumed that the decision to perform ET or CBT was random.Figure 1Decision-tree model of the culture-based treatment (CBT) and empirical treatment (ET) groups in the management of CAP.

Data Input {#S0002-S2002}
----------

Individual patient data were derived from 351 retrospective records of adult patients admitted on referral to the academic hospital of Dr. Soetomo, Indonesia, from 2014 to 2017. This hospital is a central hospital for the eastern part of Indonesia and has roughly 1,514 beds. The Center of Research and Development of Dr. Soetomo Hospital, under the ethical committee, approved the study proposal with no. 480/Panke.KKE/X/2014. The committee decided that the study did not require a review in terms of patient consent since the study was performed with retrospective observational design. We obtained the clinical data from the Department of Medical Record and all relevant costs from the Finance Department, Dr. Soetomo Hospital. The data were anonymous and confidentially. The study met the agreement with Indonesian research conduct and the Declaration of Helsinki (Ethical Principles for Medical Research Involving Human Subject version 2013).[@CIT0015]

We included hospitalized CAP cases that had both blood and sputum culture with a pneumonia severity index (PSI) class from I to V. We input data of patients whose average age was 57.6 years (min-max: 19--91 years); they were predominantly males (78.3%). We performed subgroup analyses for the implementation of CBT on patients under 60 and aged ≥60, PSI class III and above, and in the intensive care unit (ICU). We defined the age of 60 as the breakpoint for the aging population in Indonesia, according to the United Nations Population Fund (UNFPA 2014).[@CIT0016] We addressed PSI class III in subgroup analyses since this cutoff increases the risk of 30-day mortality by ten times compared to class II.[@CIT0017]

Calculation Of The Outcomes {#S0002-S2003}
---------------------------

We assessed the LE outcome in our model by adjusting the patients' ages to the average LE for the Indonesian population between 2010 and 2015 using data provided by the United Nations Department of Economic and Social Affairs, Population Division, 2017.[@CIT0018] The average LE for each group of these ages for men and women is separately presented in [Figure 2](#F0002){ref-type="fig"}. The model-time horizon was the lifetime where recovery patients would have LE greater than their ages. Considering the discount rate launched by the Health Ministry of Indonesia, we applied a 3% discount each for costs and LE.[@CIT0019]Figure 2Average remaining life expectancy of Indonesian males and females for the patient model (calculated from the United Nations Department of Economic and Social Affairs, Population Division, 2017. World Population Prospects).[@CIT0017]

Hospitalization costs were valued in US\$ with 2016 adjustments. The conversion rate to an Indonesia Rupiah (IDR) was equal to US\$ 13,308.33 according to the Organization for Economic Cooperation and Development (OECD).[@CIT0020] The costs from data were formulated as C, which is calculated from the average of the individual cost of administration (Ca), pharmacy costs (Cp), laboratory and radiology (Cl) expenses, cost of bed (Cb), and medical staff costs (Cm). The incremental cost-effectiveness ratio (ICER) in terms of total hospitalization costs and LE was calculated with the following Formula 1 below. Notably, in case the numerator was negative (cost-saving), and the denominator was positive (improving LE), then the ICER indicated dominant.

**Formula 1** Incremental cost-effectiveness ratio (ICER) calculation based on Ca, Cp, Cl, Cb, and Cm $$\documentclass[12pt]{minimal}
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[Table 1](#T0001){ref-type="table"} shows the costs and LE employed gamma and exponential distribution, respectively. According to the World Health Organization -- Choosing Interventions for Cost-Effectiveness criterion (WHO-CHOICE), a particular intervention is highly cost-effective when the ICER is less than the willingness-to-pay (WTP), defined as the Indonesian cost-effectiveness threshold of gross domestic product (GDP) per capita. If the ICER is between 1 and 3 times the GDP per capita, then the intervention is cost-effective.[@CIT0021] This definition was also applied in a previous study which was performed in Indonesia.[@CIT0022] For these thresholds, we applied the Indonesian GDP per capita in 2016 at US\$ 3,570.[@CIT0023]Table 1The Total Hospitalization Costs And Life-Expectancy Parameters For The Decision-Tree ModelParametersMeanSDMinimumMaximumDistributionHospitalization costs (US\$)AC group All cases3055.361324.611265.105879.22Gamma (5.320;0.002) Aged \< 602868.931210.451256.105612.69Gamma (5.618;0.002) Aged ≥ 603284.811435.541270.375879.22Gamma (5.236;0.002) PSI class ≥ III3125.821391.431270.375815.62Gamma (4.741;0.002) ICU4180.821434.501755.125879.22Gamma (8.494;0.002)NC group All cases2984.841364.441281.485725.82Gamma (4.786;0.002) Aged \< 602821.381441.641320.015679.82Gamma (3.830;0.001) Aged ≥ 603163.161272.821281.485725.82Gamma (6.176;0.002) PSI class ≥ III2932.671291.131281.485725.82Gamma (5.159;0.002) ICU3392.251434.901534.965560.95Gamma (5.592;0.002)ET group All cases4091.452086.941757.8610723.91Gamma (3.844;0.001) Aged \< 603387.531197.751759.196661.80Gamma (7.999;0.002) Aged ≥ 606992.351875.021770.6410411.34Gamma (13.907;0.002) PSI class ≥ III4092.312158.371757.8610723.91Gamma (3.595;0.001) ICU5666.882235.091769.2510411.34Gamma (6.428;0.001)Life-expectancy (years)AC group All cases22.1112.073.4753.26Exponential (0.5;22.11) Aged \< 6028.979.3418.8953.26Exponential () Aged ≥ 6010.054.343.4717.77Exponential (0.5;10.05) PSI class ≥ III16.439.043.7443.93Exponential (0.5;16.43) ICU16.287.707.0327.05Exponential (0.5;16.28)NC group All cases22.8012.333.7449.65Exponential (0.5;22.80) Aged \< 6029.639.6018.8949.65Exponential (0.5;29.63) Aged ≥ 6010.675.163.7417.77Exponential (0.5;10.67) PSI class ≥ III18.4311.243.7440.53Exponential (0.5;18.43) ICU25.178.707.7739.31Exponential (0.5;25.17)ET group All cases20.3110.713.7457.99Exponential (0.5;20.31) Aged \< 6027.689.2318.8957.99Exponential (0.5;27.68) Aged ≥ 609.273.993.7417.77Exponential (0.5;9.27) PSI class ≥ III15.977.413.7440.53Exponential (0.5;15.97) ICU16.767.143.4730.29Exponential (0.5;16.76)[^1]

Sensitivity Analyses {#S0002-S2004}
--------------------

We performed one-way tornado sensitivity analyses using TreeAge Pro 2019 to address the robustness of the model ICERs on the changes of the upper and lower limits of the parameter values. The parameters included in the test were costs and the probability of death being averted. The outcome of LE was conclusive as it was based on the data presented by WHO for the Indonesian population.[@CIT0018] We also conducted random probabilistic sensitivity analyses using a Monte Carlo simulation with 1,000 random cohorts on the respective corresponding distributions. We addressed a cost-effectiveness acceptability curve to draw relationships between ICER and the Indonesian affordability threshold. Indeed a relationship between the probabilistic sensitivity analysis (PSA) and univariate analysis exists in terms of input. Notably, we used the range for the input in the PSA and in the univariate analysis.

Results {#S0003}
=======

Baseline Characteristic Of The Patients {#S0003-S2001}
---------------------------------------

Concerning the change of antibiotics after culture analysis among patients in the CBT group, we determined that the AC and NC probabilities were 55.8% and 44.2%, respectively. The probability of antibiotic changes was based on microbiological evaluations and was not influenced by age or severity. This was subsequently analyzed with beta distributions. Patients' baseline characteristics of the patients and the probabilities of antibiotic changes and deaths being averted in the AC, NC, and ET groups are presented in [Table 2](#T0002){ref-type="table"}.Table 2Baseline Variables And Probabilities For The Inputs On The Decision-Tree Model And Univariate Analysis From Patient DataVariableValueDistributionBaseline (N=351) Age in years, mean (SD)57.6(15.2) Male, *n* (%)275(78.3) Aged ≥ 60, *n* (%)109(30.1) PSI class ≥ III, *n* (%)208(59.3) ICU, *n* (%)85(24.2)Probability of antibiotic changes Probability of antibiotic change after culture (AC)0.558Beta (87, 69) Probability of no-antibiotic change after culture (NC)0.442Beta (69, 87)Death averted in the AC group All cases0.793Beta (69, 18) Aged \< 600.917Beta (44, 4) Aged ≥ 600.641Beta (25, 14) PSI class ≥ III0.769Beta (40, 12) ICU0.667Beta (8, 4)Death averted in the NC group All cases0.725Beta (50, 19) Aged \< 600.889Beta (32, 4) Aged ≥ 600.546Beta (18, 15) PSI class ≥ III0.718Beta (28, 11) ICU0.556Beta (5, 4)Death averted in the ET group All cases0.579Beta (133, 82) Aged \< 600.577Beta (60, 44) Aged ≥ 600.270Beta (10, 27) PSI class ≥ III0.581Beta (68, 49) ICU0.391Beta (25, 39)[^2]

Cost-Effectiveness Analyses {#S0003-S2002}
---------------------------

The results of cost-effectiveness analyses are shown in [Table 3](#T0003){ref-type="table"}. The implementation of CBT over ET from a payer perspective was dominant, where CBT was cost-saving (US\$ 1,066,885) and improved LE (247 years) in all cases. In subgroup analyses, CBT was the most cost-saving, with an incremental cost of US\$ 3,828,006 for adults 60 years or older. Moreover, in the elderly group (aged ≥ 60), in terms of health effects, it was found that 637 life-years were saved by CBT versus ET. Even in the other categorizations, CBT performed better for both hospitalization costs and LE outcomes for patients with PSI class ≥ III or ICU patients, and the cost-effectiveness outcomes were cost-saving (dominant) compared to ET.Table 3Cost-Effectiveness Ratio For ET Versus CBT In 1,000 Patients With CAPGroupCost (US\$)LE (Years)Incremental Costs (US\$)Incremental LE (Years)CEA OutcomesAll cases ET4,074,3261,252ReferenceReference CBT3,007,4411,499−1,066,885247DominantAged \< 60 ET3,456,9921,118ReferenceReference CBT2,889,3901,861−567,602742DominantAged ≥ 60 ET7,050,151554ReferenceReference CBT3,222,1451,191−3,828,006637DominantPSI class ≥ III ET4,050,8981,189ReferenceReference CBT3,068,3811,479−982,516290DominantICU ET5,635,566842ReferenceReference CBT3,843,1461,257−1,792,420432Dominant[^3]

Univariate And Probabilistic Sensitivity Analyses {#S0003-S2003}
-------------------------------------------------

Hospitalization costs for the ET group are shown on the top of the Tornado diagrams ([Figure 3](#F0003){ref-type="fig"}), which indicate that they had the strongest effect on the ICERs out of all parameters. When hospitalization costs for the ET group increased, the ICERs decrease. In contrast, when hospitalization costs for AC and NC groups (CBT) increased, the ICERs correspondingly increased. The parameters of death averted in the CBT and ET groups were only slightly influential on ICER calculations, especially in patients with moderate-severe CAP (PSI class III-V). Tornado diagram evaluation is also provided in calculation results in [[Supplementary Table S1](https://www.dovepress.com/get_supplementary_file.php?f=224619.docx)]{.ul}.Figure 3Tornado one-way sensitivity analyses of ICER per LE comparing CBT against ET groups.**Note:** Black and grey bars indicate high and low limits, respectively.**Abbreviation:** PSI, pneumonia severity index.

The results of probabilistic sensitivity analyses on ICER values with 1,000 cohorts (Monte-Carlo simulations) between CBT and ET are shown in [Figure 4](#F0004){ref-type="fig"}. Correspondingly, [Figure 5](#F0005){ref-type="fig"} shows the acceptability probabilities at varying WTP levels. In all cases, the probabilities of cost-effectiveness acceptability in 1xWTP and 3xWTP were 75% and 83%, respectively. In the subgroup analyses of patients all ages with moderate to severe CAP (PSI class ≥ III), and in the ICU, CBT would be a cost-effective or even cost-saving approach compared to 1xGDP per capita (US\$ 3,570). CBT for patients 60 years or older represented the most cost-effective option, with acceptability values between 81% for 1xWTP and 89% for 3xWTP. The results of calculations of Monte-Carlo simulations and cost-effectiveness acceptability are available in [[Supplementary Table S2](https://www.dovepress.com/get_supplementary_file.php?f=224619.docx)]{.ul} and [[S3](https://www.dovepress.com/get_supplementary_file.php?f=224619.docx)]{.ul}, respectively.Figure 4Monte-Carlo simulations of the cost-effectiveness analyses of CBT versus ET groups using 1,000 simulations.**Note:** The circle indicates a 95% confident surface.**Abbreviations:** CAP, community-acquired pneumonia; ICU, intensive care unit; LE, life expectancy; PSI, pneumonia severity index.Figure 5Cost-effectiveness acceptability curve (CEAC) labelled on the 1xWTP (US\$ 3570.28/LE) and 3xWTP (US\$ 10,710.84).**Abbreviations:** CAP, community-acquired pneumonia; ET, empirical treatment; CBT, culture-based treatment; ICU, intensive care unit, PSI, pneumonia severity index.

Discussion {#S0004}
==========

Our findings demonstrate that treatment based on the evaluation of cultures followed by antimicrobial susceptibility testing (CBT) has advantages in terms of both cost and LE for CAP patients. CBT was dominant, not exceeding the GDP threshold in terms of cost-effectiveness (three times GDP) and even being cost-saving. Therefore, this method can reasonably be implemented for adults in general hospitals in Indonesia. Without culture analysis, treatments for CAP are more expensive and result in lost life-years, particularly for geriatric patient cases and high-severity classes of patients.[@CIT0024]--[@CIT0028] Notably, the incidence of CAP among elderly people is high since they frequently present with pre-existing immunosuppressive conditions and comorbid conditions.[@CIT0029],[@CIT0030] According to ATS/BTS, the severity of CAP infection among males was higher than females.[@CIT0031] This is the reason that males need hospitalization more than females, as reflected in the input data for our study. Also, some previous prospective studies demonstrated this issue.[@CIT0031]--[@CIT0033]

In non-ICU hospitalization, culture analysis is one of the procedures recommended by the Infectious Diseases Society of America (IDSA) and ATS to guide antibiotic use for CAP patients.[@CIT0004] The implementation of the guidelines with the threshold of US\$ 100,000/QALY (quality-adjusted life years) leads to cost-savings of US\$ 799 to US\$ 1,379 per patient and improved quality of life, particularly in elderly people.[@CIT0034] In the ICU, it is essential to considered CBT implementation since the use of antibiotic is costly. A previous study conducted in an LMIC reported that antibiotic utilization for CAP patients in ICU was determined as the highest proportion (38%) of total hospitalization costs.[@CIT0035]

The assessment of severity using the PSI score resulted in higher sensitivity of sputum culture analyses. Gram staining and sputum culture procedures are very useful for inpatient treatment plans and ICU patients, guiding CAP diagnosis and antimicrobial selection.[@CIT0036] The organisms from the microbiological culture are more likely to accurately represent respiratory tract pathogens in CAP patients.[@CIT0037] Furthermore, the implementation of blood and sputum culture analysis should be considered in patients with moderate and severe CAP with poor clinical prognosis and who are considerably susceptible to bacteremia.[@CIT0038],[@CIT0039]

Culture analysis is part of diagnostic stewardship that supports antimicrobial identification and infection prevention programs. CBT should be part of such integrated management within a theragnostic approach, involving multi-disciplines, and leading personalized management, improvement of prescriptions for treatment, improved clinical outcomes, and decreasing costs.[@CIT0040],[@CIT0041] An issue of concern is the potential contamination of biological specimens. Contaminated blood and sputum cultures could extend costs and have adverse effects.[@CIT0042],[@CIT0043] The role of the clinical microbiologist is critical at this point for screening assessments of the quality of the sample. Recently, several advanced methods to reduce contaminations have been developed, such as matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) and multiplex nucleic acid amplification test (NAAT).[@CIT0044],[@CIT0045] However, these methods are costly.

To our knowledge, this study is the first cost-effectiveness analysis for culture analysis in CAP patients considering real-world data and the impact of the effect of culture analysis in terms of changes in antibiotic treatments, particularly in an LMIC setting. The utility impact was accounted for the overall population as well as relevant subgroups of patients aged ≥ 60, with PSI class ≥ III and in the ICU. This approach provided the necessary level of granularity. However, this study has some limitations. First, community data from primary healthcare was not available. There is a lack of sample data related to CAP in the community since facilities for clinical diagnostics and bacterial identification remain unavailable, and these are not routine procedures, especially in remote areas. In clinical practice, we assumed randomness in the decision to do ET or CBT, as confirmed by the clinicians. However, we could not exclude that in some specific cases some aspect, may still have influential this decision and so probably introducing some bias in our analysis. Second, this study used a retrospective dataset; patients with incomplete data related to ICER outcomes could not be analyzed. In further investigations comparing the effects of treatments, randomized controlled clinical trials are necessary to obtain additional results. As such, our study can be considered as hypothesis generating rather than providing final evidence. Lastly, we did not include costs associated with the side effects of the treatments in the present research. Common undesirable side effects of antibiotic treatment, such as diarrhea, *Clostridium difficile* infections, and allergic reactions can extend the length of hospitalization and increase costs.[@CIT0046]

Conclusion {#S0005}
==========

In conclusion, CAP patients undergoing treatments based on culture analyses (CBT) were estimated to receive benefits in terms of cost-savings and increased LE than those with empirical treatment (ET) during their hospitalization; CBT was labeled dominant compared to ET. Notably, the implementation of CBT provides considerable advantages for patients all ages as well as for higher severity classes. Most notably in severe CAP cases, cultures can adequately guide antibiotic selection for patients with PSI class III or above or who are hospitalized in ICUs.

We would like to thank Simon van der Pol who was involved in discussions on LE calculations of the patients. The work was supported by a grant from the Directorate General of Higher Education (DIKTI), Ministry of Research, Technology and Higher Education of the Republic of Indonesia \[No.224/D3.2/PG/2016\].

Abbreviations {#S0006}
=============
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[^1]: **Abbreviations:** Group AC, antibiotic change after culture; group NC, no antibiotic change after culture; group ET, empirical antibiotics only.

[^2]: **Abbreviations:** Group AC, antibiotic change after culture; group NC, no antibiotic change after culture; group ET. empirical antibiotics only.

[^3]: **Abbreviations:** CEA, cost-effectiveness analyses; ET, empirical treatment; ICU, intensive care unit; LE, life expectancy; US\$, US dollar; PSI, pneumonia severity index; CBT, culture-based treatment.
